The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

Medtronic ( MDT 2.27%) and Johnson & Johnson ( JNJ 1.64%) are two very healthy, high-yielding dividend stocks. This makes ...

Medical device manufacturer Medtronic (NYSE: MDT) is a healthcare industry stalwart. The company, based in the U.S. and ...

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success ...

The revenue miss came as sales at Medtronic's Medical Surgical division declined 1.9% to $2.07 billion. The company pointed ...

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

Medtronic's FDA-approved BrainSense Adaptive DBS system revolutionizes Parkinson's therapy with real-time adjustments for ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...

Jeff Jonas, portfolio manager at Gabelli Funds, said he’s surprised at the drop in Medtronic’s stock on the heels of its ...

The massive robot-making, pacemaker-inventing medtech company Medtronic is facing a financial snag: the humble stapler.